Association between beta‐blocker atenolol use and prostate cancer upgrading in active surveillance1
Open Access
- 9 October 2024
- journal article
- research article
- Published by Wiley in BJUI Compass
- Vol. 5 (11) , 1209-1214
Abstract
Objectives: The objective of this study is to investigate the association between the use of beta‐adrenergic antagonist atenolol and risk of pathologic upgrade in patients on active surveillance, considering growing literature implicating adrenergic innervation with disease progression mediated through beta‐adrenergic signalling.Patients and Methods: Men with low‐risk or favourable intermediate‐risk prostate cancer who were placed on an active surveillance protocol between 2006 and 2020 across three diverse urban hospitals were included. Exposure was duration of atenolol use, and outcome was pathologic grade group upgrading (to GG ≥ 3) on final prostate biopsy. Cox proportional hazard regression models were used to determine the associations between atenolol use and risk of upgrading with time, on a per‐examination basis.Results: A total of 467 men with initial GG ≤ 2 were included. Postdiagnosis atenolol use was associated with a decreased risk of pathologic upgrade to GG ≥ 3 on final repeat biopsy (HR 0.81, 95% CI 0.39–0.98). Longer duration of postdiagnosis atenolol use (>2 years) and greater cumulative atenolol dose (>730 defined daily doses) were associated with a more pronounced decreased risk of upgrade to GG ≥ 3 (HR 0.41, 95% CI 0.05–0.88, and HR 0.32, 95% CI 0.15–0.99, respectively). Initiation of atenolol use prior to prostate cancer diagnosis had a slightly greater protective effect than drug initiation postdiagnosis (HR 0.79, 95% CI 0.43–0.98, and HR 0.83, 95% CI 0.30–0.99, respectively).Conclusions: Beta‐adrenergic blockade with atenolol use in men on active surveillance is associated with a reduced risk for clinically significant grade group pathologic upgrade.Keywords
This publication has 33 references indexed in Scilit:
- Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate CancerJAMA Oncology, 2022
- Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer RecurrenceJAMA Network Open, 2022
- Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active SurveillanceEuropean Urology Oncology, 2020
- Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015JAMA, 2019
- Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective TrialEuropean Urology, 2019
- Beta-blockers for hypertensionCochrane Database of Systematic Reviews, 2017
- Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population‐based case–control studyInternational Journal of Cancer, 2015
- Association Between Use of β-Blockers and Prostate Cancer–Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic DiseaseEuropean Urology, 2014
- Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugsInternational Journal of Cancer, 2004
- Chronopharmacokinetics of beta-receptor blocking drugs of different lipophilicity (propranolol, metoprolol, sotalol, atenolol) in plasma and tissues after single and multiple dosing in the ratNaunyn-Schmiedeberg's Archives of Pharmacology, 1985